Drug intelligence / Profile preview

omega-3 fatty acids

Development stage
Discontinued
Lead developer
Centre Hospitalier Universitaire de Nice
Modality
Small Molecules
Administration
Oral
01

Overview

Omega-3 fatty acids are polyunsaturated fatty acids (PUFAs) characterized by a double bond at the third carbon atom from the end of the carbon chain. In the context of the study by Centre Hospitalier Universitaire de Nice, a specific supplementation regimen (1,650 mg/day) was evaluated for its potential to reduce liver volume (hepatomegaly) and fat content (hepatic steatosis) in morbidly obese patients prior to bariatric surgery. The rationale was that omega-3 PUFAs, such as eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), can modulate lipid metabolism, reduce inflammation, and inhibit lipogenesis. However, a multicenter randomized controlled trial (NCT03006016) concluded that a 4-week preoperative course did not significantly reduce liver volume or steatosis compared to placebo.

Other names
n-3 PUFAn3 PUFAn 3 PUFAomega-3 polyunsaturated fatty acidsomega3 polyunsaturated fatty acidsomega 3 polyunsaturated fatty acidsfish oilomega-3-acid ethyl estersomega3-acid ethyl estersomega 3-acid ethyl esters
02

Targets

SREBP-1 / SREBF1 (SREBP-1)PPARG (Peroxisome proliferator-activated receptor gamma)PPARA (Peroxisome proliferator-activated receptor alpha)NR1H3 (Liver X receptor beta)

Beyond the preview

Go deeper on omega-3 fatty acids.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on omega-3 fatty acids.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call